News

ALS research is at a time of unprecedented advancement and Canada’s world-class ALS research community – along with international ALS researchers and experts – are accomplishing more than ever before. With new advancements being announced daily, the ALS Canada Research…

Highlights: On October 4, Health Canada approved Radicava (edaravone) for the treatment of ALS. Health Canada’s terminology for this approval is called a Notice of Compliance, or NOC. The approval follows a 180-day priority review of the drug. Approval from…

Updated October 17, 2018 The first ALS gene was discovered over two decades ago. By the end of 2017, scientists had found more than 25 genes. By studying these genes that are involved in familial ALS, which accounts for 5 to…

The result of the 2014 Ice Bucket Challenge gave the ALS community a tremendous gift: awareness and unprecedented investment in ALS research. Thanks to the viral fundraising phenomenon that year, along with matched funds from Brain Canada (through the Canada…

2017 Annual Report to the community In 2014, the Ice Bucket Challenge gave hope to people and families living with ALS – hope that one day there would be a cure for this terminal disease. With the Ice Bucket…

Updated July 18, 2018 The Canadian Agency for Drugs and Technologies in Health (CADTH) recently posted an open call for patient input on Radicava (edaravone). This is an additional step along the approval and affordability pathway for the drug, which…

ALS research is at a time of unprecedented advancement. Our biggest hope is to stop ALS from stealing dreams, abilities, and lives – and researchers are closer than they’ve ever been to making this a reality. With such unprecedented momentum,…

New research from the University of Toronto and the University of Cambridge, funded in part by the Ice Bucket Challenge and the ALS Society of Canada’s partnership with Brain Canada, is having an impact on our understanding of ALS and…